AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$TWST

Leproust Emily M. sold $8.8M of TWST

Leproust Emily M. (Chief Executive Officer) sold 46,391 shares of Twist Bioscience Corp (TWST) at an average of $189.04 ($188.88–$200.00, $8.77M total) across 2 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Oct 5, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
high confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership and may be interpreted as a lack of confidence, potentially prompting short‑term price weakness.

02

Market read

Insider sale of a significant size by the CEO could influence short‑term trading sentiment for TWST.

03

What to watch

Potential upcoming financing needs or personal liquidity requirements for the CEO.

Relevance 5/10Novelty 6/10Timing: post‑market filing on 2026‑10‑05

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$TWSTBearishHigh confidence
Context

CEO Emily Leproust sold $8.8M of Twist Bioscience shares via a 10b5‑1 plan, reducing her stake to 567,308 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A senior executive's sizable open‑market sale of nearly $9M is material and often interpreted as a negative signal.

Market effects

Sector

May raise concerns for biotech investors about insider sentiment at Twist Bioscience.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond Twist Bioscience shareholders.

Counterpoint

What could challenge this read

The sale could be a routine 10b5‑1 execution unrelated to company fundamentals.

Key entities

  • company
    Twist Bioscience Corp

    Biotech company specializing in DNA synthesis.

  • person
    Emily M. Leproust

    Chief Executive Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min